Meanwhile, Daud et al27 found that administering 180 mg of TRF daily for 16 weeks to individuals with end-stage renal disease led to a significant increase in apolipoprotein A1 (ApoA1) and HDL-C, as well as a significant decrease in plasma triacylglycerol (TG), LDL-C, and cholesteryl-ester transfer. Here, APOA1 is linked to stage 5 chronic kidney disease.